ARTA
IDIX

A.R.T. Advisors’s IDENIX PHARMACEUTICALS INC IDIX Stock Holding History

A.R.T. Advisors’s Portfolio IDIX Stock Details IDIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-23,265
Closed -$120K – 1754
2013
Q3 		$120K Buy
+23,265
New +$102K 0.01% 1198

Other funds holding IDIX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

A.R.T. Advisors's IDIX Position: Q4 2013 in Review

A.R.T. Advisors sold out of IDENIX PHARMACEUTICALS INC (IDIX) in Q4 2013, closing a stake of 23,265 shares — an estimated $120K sold.

A.R.T. Advisors first reported a position in IDIX in Q3 2013 and held it in 1 quarter. The position peaked at $120K in Q3 2013. 88 funds tracked by Wall St. Rank hold IDIX as of Q4 2013.

  • A.R.T. Advisors reported no remaining IDENIX PHARMACEUTICALS INC position as of Q4 2013 after selling out during the quarter.
  • A.R.T. Advisors sold 23,265 IDENIX PHARMACEUTICALS INC shares in Q4 2013, an estimated $120K.
  • A.R.T. Advisors first reported a position in IDENIX PHARMACEUTICALS INC in Q3 2013 and held it in 1 quarter.
  • A.R.T. Advisors's IDENIX PHARMACEUTICALS INC position peaked at $120K in Q3 2013.
  • 88 funds tracked by Wall St. Rank held IDENIX PHARMACEUTICALS INC as of Q4 2013.

Based on A.R.T. Advisors's 13F filing for Q4 2013, filed 14 Feb 2014.